Stryker Q2 net sales up 11.1% to $6.0 bln, EPS increases 7.0%.

• Stryker Q2 2025: $6.0bn net sales, 11.1% increase • Organic net sales up 10.2% • Reported EPS up 7.0% to $2.29 • Adjusted EPS up 11.4% to $3.13 • Reported operating income margin at 18.5% • Adjusted operating income margin at 25.7%, up 110 bps • MedSurg and Neurotechnology sales up 11.0% • Orthopaedics sales up 9.0%

Stryker Corporation (NYSE: SYK) has reported robust financial performance for the second quarter of 2025, with net sales increasing by 11.1% to $6.0 billion. This growth was driven by organic net sales growth of 10.2%, with unit volume contributing 9.7% to the increase and higher prices adding 0.5% [2].

The company's earnings per share (EPS) also showed strong growth, with reported EPS up 7.0% to $2.29 and adjusted EPS up 11.4% to $3.13. The adjusted operating income margin improved by 110 basis points to 25.7%, reflecting effective cost management despite inflationary pressures [2].

Stryker's MedSurg and Neurotechnology segment led the growth, with net sales increasing by 17.3% to $3.8 billion, while the Orthopaedics segment showed more modest growth of 2.0% to $2.2 billion. Excluding the impact of the divested Spinal implant business, the Orthopaedics segment's growth was 10.7% in constant currency [2].

The company's balance sheet shows strategic capital deployment, with $2.4 billion in cash and cash equivalents and an increase in inventories to $5.3 billion from $4.8 billion at year-end 2024 [2].

Stryker has raised its 2025 guidance, now expecting organic net sales growth of 9.5% to 10.0% and adjusted EPS of $13.40 to $13.60. The company's strong performance and strategic initiatives position it well to capitalize on emerging market opportunities [2].

References:
[1] https://www.ainvest.com/news/stryker-syk-q2-2025-earnings-preview-upside-anticipated-streamlining-efforts-strategic-divestiture-2507/
[2] https://www.stocktitan.net/news/SYK/stryker-reports-second-quarter-2025-operating-80925cuj2tdf.html